Disclaimer: The following content discusses our Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by our FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoCath-enabled TAMP with gemcitabine for the treatment of locally advanced pancreatic cancer (LAPC) is being studied under an IND. This combination product candidate has not been approved by FDA for commercial use and its safety and effectiveness in treating LAPC has not been established. For RenovoCath’s Indications for Use and safety information, please visit IFU-10004-Rev.-G-Universal-IFU.pdf.

Could a New Approach to Chemotherapy Change the Future of Pancreatic Cancer?

Living Hope Logo

Dr. Jonathan Kessler, Chief of Interventional Radiology at City of Hope, recently joined the Living Hope Podcast to discuss his work with a multidisciplinary oncology team treating pancreaticcancer and the need for new treatment options.

View the entire article on Living Hope